Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Esketamine for Treatment-Resistant Depression (SYNAPSE)
NCT01998958Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Started Jan 2014; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT01998958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998958.